Advertisement

Topics

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Receives Orphan Designation for Lenabasum

10:49 EDT 18 Sep 2018 | BiotechStocks.com

Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the European […]

The post Corbus Pharmaceuticals Holdings, Inc. (CRBP) Receives Orphan Designation for Lenabasum appeared first on Biotech Stocks | Biotechnology Investments and News. The Future of Innovation & Discovery..

Original Article: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Receives Orphan Designation for Lenabasum

NEXT ARTICLE

More From BioPortfolio on "Corbus Pharmaceuticals Holdings, Inc. (CRBP) Receives Orphan Designation for Lenabasum"

Advertisement
Quick Search
Advertisement
Advertisement